Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. SPY
5. META
6. MSFT
7. GOOGL
8. GMAB
9. AMD
10. BBIO

Go back to Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 7c

Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

August 7, 2018 7:30 AM EDT

Plan to Open Expansion Cohorts in Phase 1 Trial of SY-1365 in Fall of 2018; Expansion to Focus on Ovarian and Breast Cancer Patient Populations as Single Agent and in Combination

Expect to Report Initial Clinical Data from Combination Arms of Phase 2 Trial of SY-1425 and Dose Escalation Portion of Phase 1 Trial of SY-1365 in Fourth Quarter of 2018

EMA Grants SY-1425 Orphan Drug Designation for Treatment of AML

Management to Host Conference Call at 8:30 AM ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:... More